NEW YORK (TheStreet) -- Bluebird Bio (BLUE - Get Report) surged to a 52-week high of $41.77 on Monday after the company reported positive results on Saturday from its gene therapy for the blood disorder beta-thalassemia.
The company announced that two patients with the blood disorder were able to cease blood transfusions after one treatment with BlueBird's experimental gene therapy called LentiGlobin, which replaces the defective gene with a fully functional one.
The stock was up 34.73% to $35.15 at 11:56 a.m. More than 4.2 million shares had changed hands, compared to the average volume of 239,356.
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts